Letrozol Ratiopharm (Letrozole)

Letrozole blocks the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. By inhibiting this conversion, circulating estrogen levels fall dramatically, depriving estrogen‑dependent breast cancer cells of a key growth stimulus.

The specific dose of Letrozol Ratiopharm is determined by the prescribing physician based on the patient’s clinical condition, treatment setting, and individual factors. Dosage decisions are made by qualified healthcare professionals and are not standardized in public information.

Letrozole is contraindicated in pregnancy because it can harm a developing fetus by suppressing estrogen. It is also not recommended during breastfeeding, as it may pass into breast milk and affect the infant. Women of childbearing potential should use effective contraception while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to letrozole is tamoxifen, a selective estrogen receptor modulator. While tamoxifen blocks estrogen receptors, letrozole reduces estrogen production itself. In postmenopausal women, letrozole often provides greater suppression of estrogen and may be preferred in certain adjuvant or metastatic scenarios.

Letrozol Ratiopharm tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, excessive heat and direct sunlight to maintain stability and potency.

Letrozol Ratiopharm is taken orally, usually once daily, with or without food. The tablet is swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include severe bone loss leading to osteoporosis or fractures, thromboembolic events such as deep‑vein thrombosis, liver function abnormalities, interstitial lung disease, and rare cardiac arrhythmias due to QT prolongation. Patients should report any new symptoms promptly.

Letrozol Ratiopharm should not be used by pregnant women, women who are breastfeeding, or individuals with known hypersensitivity to letrozole or any tablet excipients. Caution is also advised for patients with severe liver impairment or uncontrolled cardiovascular disease.